Eye Catching Stocks : BP p.l.c. (NYSE:BP), Intel (NASDAQ:INTC), Bristol-Myers Squibb (NYSE:BMY), BioScrip Inc. (NASDAQ:BIOS), Willis Group Holdings Public Company (NYSE:WSH),

BP plc (NYSE:BP)‘s stock had its “neutral” rating reissued by analysts at Oddo & Cie in a research report issued to clients and investors on Friday. They currently have a GBX 510 ($8.29) price target on the stock. Oddo & Cie’s price objective suggests a potential upside of 8.48% from the stock’s previous close. BP p.l.c. (NYSE:BP)’s stock on 15 September traded at beginning with a price of $45.59 and when day-trade ended the stock finally decreased -0.11% to end at $45.89. BP p.l.c. (NYSE:BP)’s showed weekly performance of 1.24%.

Intel Corporation (NASDAQ:INTC) is aiming for a future where cables are not necessary for computers as the company recently highlighted WiGig, a fast Wi-Fi standard, and wireless charging at the Intel Developer Forum 2014 (IDF14). Intel Corporation (NASDAQ:INTC) on Monday closed at $34.54. Stock institutional ownership is 66.00% while insider ownership includes 0.07%. Intel Corporation (NASDAQ:INTC) distance from 50-day simple moving average (SMA50) is 2.58%.

Merck & Co., Inc. (MRK) won the US Food and Drug Administration’s (FDA) Accelerated Approval for its breakthrough cancer therapy, Keytruda. It beat Bristol-Myers Squibb Company (NYSE:BMY) by becoming the first company first to get approval for a PD-1 inhibitor drug in the US. Keytruda has been approved for the treatment of advanced melanoma in patients who have failed treatments with Bristol-Myers’ Yervoy and other drugs. The PD-1 inhibitor drug belongs to a new generation of drugs which boost the patient’s immune system to fight cancerous cells. Merck expects to launch Keytruda within one week. Bristol-Myers Squibb Company (NYSE:BMY)’s shares on Monday traded in the range of 49.75 – 50.37and ended up on $49.95. Bristol-Myers Squibb Company (NYSE:BMY) distance from 200-day simple moving average (SMA200) is -0.92%. BMY’s sales growth for past 5 years was -1.50% and its EPS growth for past 5 years was -3.60%.

BioScrip Inc. (NASDAQ:BIOS) has been divesting assets for a year now, but the health services company could find itself a target for both large strategic and financial players because of the strength of its in-home medicine business, according to industry sources. BioScrip Inc. (NASDAQ:BIOS)’s stock on 15 September decreased -2.22% to the closing price of $7.93. Its fifty two weeks range is $5.61 – 11.95. The total market capitalization recorded $544.1M. BioScrip Inc. (NASDAQ:BIOS) monthly performance is -0.63%.

Keefe, Bruyette & Woods upgraded shares of Willis Group Holdings PLC (NYSE:WSH) from a market perform rating to an outperform rating in a report issued on Tuesday. They currently have $49.00 target price on the stock, up from their previous target price of $46.00. Willis Group Holdings Public Limited Company (NYSE:WSH) on Monday closed at $42.55. Stock institutional ownership is 97.30% while insider ownership includes 0.20%. Willis Group Holdings Public Limited Company (NYSE:WSH) distance from 50-day simple moving average (SMA50) is 1.58%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone